Onesource Specialty Pharma working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
245.04×245.04×132.62×
142.09×142.09×105.24×
225.76×225.76×147.26×
161.37×161.37×90.60×
49.71×−88.69×−52.77×
0.18×0.18×0.19×
−0.12×−0.12×1.20×
0.03×0.03×−0.05×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,991 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)132.62245.04245.04
Receivable Days (DSO)105.24142.09142.09
Payable Days (DPO)147.26225.76225.76
Cash Conversion Cycle (days)90.60161.37161.37
Working Capital Turnover-52.77-88.6949.71
Asset Turnover0.190.180.18
Cash Conversion (CFO/Net Income)1.20-0.12-0.12
CFO/EBITDA-0.050.030.03
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.